Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study
Gianpiero Benetti(ASST Melegnano e della Martesana), G. Bellati(Fondazione Ricerca Molinette), Guido Croce(Ospedale San Carlo), Mauro Borzio(Ospedale Papa Giovanni XXIII), F. Balzola, Mario Rizzetto(University of Turin), Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alberto Colombo(University of Illinois Chicago), Carlo Iamoletti(Azienda Ospedaliera Treviglio), G Ramella
Cited by 1
Related Papers
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
|Hepatology|2003|2.7k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
|Diabetologia|2005|759